DDrare: Database of Drug Development for Rare Diseases

Immune globulin intravenous (human), 10% triple virally reduced solution (DrugBank: -)

告示番号	疾患名（ページ内リンク）	臨床試験数
63	特発性血小板減少性紫斑病	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00162006 (ClinicalTrials.gov)	January 1, 2003	8/9/2005	Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura	Prospective Open-Label Study of the Efficacy and Safety of Immune Globulin Intravenous (Human), 10% TVR Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura	Immune Thrombocytopenic Purpura (ITP)	Drug: Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution	Baxalta now part of Shire	NULL	Completed	18 Years	65 Years	All	28	Phase 2	Czechia;Germany;Hungary;Poland;Czech Republic

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00162006
(ClinicalTrials.gov)

January 1, 2003

8/9/2005

Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura

Prospective Open-Label Study of the Efficacy and Safety of Immune Globulin Intravenous (Human), 10% TVR Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura

Immune Thrombocytopenic Purpura (ITP)

Drug: Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution

Baxalta now part of Shire

NULL

Completed

18 Years

65 Years

All

Phase 2

Czechia;Germany;Hungary;Poland;Czech Republic